ESR1 and cancer: Whereas hybrid ligands combining antiestrogens with other classes of anticancer drugs represent without doubt valuable pharmacological tools and can be considered as an attempt to carrier drug delivery (estrogen receptor pharmacophore “delivers” the hybrids to cancer cells overexpressing estrogen receptors), a question remains whether they are superior to a combination of both single drugs in a clinical setting.